DelveInsight launched its new report on Peanut Allergy Pipeline Insight, 2020
“Peanut Allergy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peanut Allergy market. A detailed picture of the Peanut Allergy pipeline landscape is provided, which includes the disease overview and Peanut Allergy treatment guidelines. The assessment part of the report embraces in-depth Peanut Allergy commercial assessment and clinical assessment of the Peanut Allergy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peanut Allergy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key facts of the report:1. France had the highest prevalent population of Peanut Allergy with 614,959 cases, followed by Germany and the United Kingdom.2. The total cases of mild and moderate to severe Peanut Allergy in the US varied as 2,341,384 and 1,153,219 respectively.
Report insights: 1. All of the companies that are developing therapies for the treatment of Peanut Allergy with aggregate therapies developed by each company for the same.2. Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Peanut Allergy treatment.3. Peanut Allergy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Download free report: https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight
Table of contents:
1. Report Introduction2. Peanut Allergy 2.1. Overview2.2. History 2.3. Peanut Allergy Symptoms2.4. Causes2.5.Pathophysiology2.6. Peanut Allergy Diagnosis 2.6.1. Diagnostic Guidelines3. Peanut Allergy Current Treatment Patterns3.1. Peanut Allergy Treatment Guidelines4. Peanut Allergy – DelveInsight’s Analytical Perspective4.1. In-depth Commercial Assessment4.1.1. Peanut Allergy companies collaborations, Licensing, Acquisition -Deal Value Trends4.1.1.1. Assessment Summary4.1.2. Peanut Allergy Collaboration Deals4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis4.1.2.3. Peanut Allergy Acquisition Analysis5. Therapeutic Assessment5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development5.1.2. Assessment by Product Type (Mono / Combination)5.1.2.1. Assessment by Stage and Product Type5.1.3. Assessment by Route of Administration5.1.3.1. Assessment by Stage and Route of Administration5.1.4. Assessment by Molecule Type5.1.4.1. Assessment by Stage and Molecule Type5.1.5. Assessment by MOA5.1.5.1. Assessment by Stage and MOA5.1.6. Assessment by Target5.1.6.1. Assessment by Stage and Target6. Peanut Allergy Late Stage Products (Phase-III)7. Peanut Allergy Mid Stage Products (Phase-II)8. Early Stage Products (Phase-I)9. Pre-clinical Products and Discovery Stage Products10. Inactive Products11. Dormant Products12. Peanut Allergy Discontinued Products13. Peanut Allergy Product Profiles13.1. Drug Name: Company 13.1.1. Product Description13.1.1.1. Product Overview13.1.1.2. Mechanism of action13.1.2. Research and Development13.1.2.1. Clinical Studies13.1.3. Product Development Activities13.1.3.1. Collaboration13.1.3.2. Agreements13.1.3.3. Acquisition 13.1.3.4. Patent Detail13.1.4. Tabulated Product Summary13.1.4.1. General Description TableDetailed information in the report14. Peanut Allergy Key Companies15. Peanut Allergy Key Products16. Dormant and Discontinued Products16.1. Dormant Products16.1.1. Reasons for being dormant16.2. Discontinued Products 16.2.1. Reasons for the discontinuation17. Peanut Allergy Unmet Needs18. Peanut Allergy Future Perspectives19. Peanut Allergy Analyst Review 20. Appendix21. Report Methodology21.1. Secondary Research21.2. Expert Panel Validation
Related reports:
Peanut Allergy – Epidemiology Forecast to 2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/